Latest Biotest AG Stories

BOCA RATON, Fla. and DREIEICH, Germany, Feb. 4, 2013 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC) a wholly owned U.S. subsidiary of Biotest AG, is pleased to announce the first commercial sales and successful shipments of BIVIGAM(TM) [Immune Globulin Intravenous (Human), 10% Liquid] into the pharmaceutical distribution channel for use by physicians, pharmacists and hospitals throughout the United States. The product is now available on a regular basis for patients with...

BOCA RATON, Fla. and DREIEICH, Germany, Jan. 31, 2013 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM(TM), its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI). BIVIGAM is the first new intravenous immune globulin (IVIG) to be approved by the FDA with a validated assay for measuring...

BOCA RATON, Fla., Jan. 10, 2013 /PRNewswire/ -- Biotest Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of Biotest AG (Dreieich, Germany), today announced it has entered into a strategic long-term manufacturing, supply, and license agreement with ADMA Biologics, Inc. (ADMA). Under the terms of the agreement, ADMA has agreed to purchase exclusively from BPC its worldwide requirements of RSV (Respiratory Syncytial Virus) Immune Globulin manufactured from human plasma...

DREIEICH, Germany and BOCA RATON, Fla., Dec. 20, 2012 /PRNewswire/ -- Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for BIVIGAM(TM) for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration (FDA). BIVIGAM is the first polyspecific intravenous immune globulin manufactured in the U.S. by Biotest Pharmaceuticals Corporation (BPC) at its Boca Raton, Florida facility. This product is...

BOCA RATON, Fla., March 8, 2012 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a wholly-owned subsidiary of Biotest AG (Dreieich, Germany), announced the appointment of Jordan Siegel as the Company's Chief Executive Officer, effective May 1, 2012. Dr. Georg Floss, BPC's interim CEO, will be returning to Germany on April 30th after successfully completing his assignment to assume the role of Global Head of Operations for Biotest AG. "I would like to thank Dr. Floss for...

ABBOTT PARK, Ill. and DREIEICH, Germany, June 21, 2011 /PRNewswire/ -- Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway to study its potential use in other immune-related diseases. CD4 is expressed on T-cells and is involved in T-cell mediated modulation...

BOCA RATON, Fla., Feb. 11 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG, Dreieich, Germany, announced that it has acquired a plasma collection facility located at 2860 Cerrillos Road, Santa Fe, New Mexico from Talecris Plasma Resources, Inc. With this acquisition, BPC now operates 11 plasma centers in various locations throughout the United States. Last year, the company announced it had aggressive plans for further expansion during...

Biotest Diagnostics Corporation (Biotest) and Group Services for America's Blood Centers (GSABC), a cooperative wholly owned by America's Blood Centers (ABC), announced today their multi-year supply agreement for Biotest blood bank products including the Biotest traditional blood bank reagents and the TANGO(R) optimo Automated Blood Bank System, reagents, consumables and service. Biotest is a subsidiary of Biotest AG, a worldwide supplier of manual and automated solutions to the blood bank...

ROCKAWAY, N.J., Aug. 18 /PRNewswire/ -- Biotest Diagnostics Corporation (Biotest) -- the U.S. subsidiary of German-based Biotest AG, a worldwide supplier of traditional and automated blood bank solutions -- announces that it has received final clearance from the U.S. Food and Drug Administration (FDA) to begin marketing its full line of traditional blood bank reagents in North America. Intended for use by donor centers, reference laboratories and hospitals for blood group serology testing,...